Memo Therapeutics AG's Potravitug Granted Orphan Designation in the European Union GlobeNewswire December 18, 2025 PRESS RELEASE Memo Therapeutics AG's Potravitug Granted Orphan Designation in the European Union Orphan designation confers market exclusivity, regulatory and financial benefits for medicines intended to treat rare diseases Recognizes both medical plausibility of the initial clinical data and that […]

Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's Disease GlobeNewswire December 18, 2025 Results showed CNS target engagement with reduction in GCase substrate glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF), a prespecified endpoint The reduction in GluSph in CSF, a first-ever observation following

Atavistik Bio Raises $120 Million Series B Financing to Advance the Development of Selective Allosteric Small Molecule Therapeutics for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT) and Myeloproliferative Neoplasms (MPNs) GlobeNewswire December 18, 2025 Proceeds will support the advancement of Atavistik Bio's oral allosteric AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia (HHT) and the JAK2 V617F

Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire December 18, 2025 SEATTLE, Dec. 18, 2025 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that Thijs Spoor, Chief Executive Officer, will present

— Receives U.S. Food and Drug Administration (FDA) Approval for Generic Version of Sandostatin® LAR Depot (Octreotide Acetate for Injectable Suspension) — U.S. FDA Accepts New Drug Application for Low Dose Estrogen Weekly Patch for Contraception — U.S. FDA Clears Investigational New Drug Application for MR-146 in Neurotrophic Keratopathy — Japan Pharmaceuticals and Medical Devices

According toMarketsandMarkets™, The liquid biopesticides marketis projected to grow from USD 5.76 billion in 2025 and to reach USD 11.50 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 14.8% during the forecast period. https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg Browse250 market data Tables and90 Figures spread through310 Pages and in-depth TOC on”Liquid Biopesticides Market – Global Forecast

Today, Core Natural Resources, Inc. (NYSE: CNR) (“Core,” the “company,” “we” or “our”) announced that it has resumed longwall operations at its Leer South metallurgical mine in Barbour County, West Virginia. The longwall system had been idle since January 13, 2025, when combustion-related activity was detected in a previously mined area. https://mma.prnewswire.com/media/2681943/Core_Horizontal_PMS_Full_YG_Logo.jpg In addition, Core

BD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person Immune Profiling Study BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a strategic collaboration with the Institute for Immunology and Immune Health (I3H) at the University of

In ATTAIN-MAINTAIN, orforglipron achieved the primary and all key secondary endpoints for weight maintenance vs. placebo at 52 weeks following weight loss on Wegovy or Zepbound Participants who switched to orforglipron from Wegovy maintained all but 0.9 kg of their previously achieved weight loss on average Lilly has submitted orforglipron to the U.S. Food and

Marathon Petroleum Corp. (NYSE: MPC) today announced that Maria A. Khoury will join the company as Executive Vice President and Chief Financial Officer, effective January 19, 2026. Khoury will succeed John J. Quaid, who will remain with the company for a period of transition. “Maria's deep financial operations expertise and broad industry experience from 25